Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly
Jun 24
Swedish (OMX) Biotech Industry Analysis
UpdatedJul 01, 2024
DataAggregated Company Financials
Companies64
- 7D1.5%
- 3M7.6%
- 1Y15.5%
- YTD-3.0%
In the last week, the Biotech industry is up 2.6%, with Swedish Orphan Biovitrum up 2.6%. During this same period, the Egetis Therapeutics underperformed, falling 26%. This takes the industry's 12 month performance to a gain of 14%. As for the next few years, earnings are expected to grow by 39% per annum.
Industry Valuation and Performance
Has the Swedish Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 01 Jul 2024 | SEK 196.6b | SEK 30.6b | -SEK 5,537,729,202.10 | 39.3x | -35.5x | 6.4x |
| Wed, 29 May 2024 | SEK 191.1b | SEK 30.6b | -SEK 5,400,007,476.44 | 39.1x | -35.4x | 6.2x |
| Fri, 26 Apr 2024 | SEK 182.4b | SEK 30.8b | -SEK 5,554,927,800.43 | 54.1x | -32.8x | 5.9x |
| Sun, 24 Mar 2024 | SEK 184.6b | SEK 29.8b | -SEK 5,636,766,957.11 | 58.7x | -32.8x | 6.2x |
| Tue, 20 Feb 2024 | SEK 179.6b | SEK 29.7b | -SEK 5,699,202,242.06 | 50.5x | -31.5x | 6x |
| Thu, 18 Jan 2024 | SEK 186.9b | SEK 28.7b | -SEK 1,200,066,697.00 | 59x | -155.7x | 6.5x |
| Sat, 16 Dec 2023 | SEK 196.9b | SEK 28.7b | -SEK 1,170,293,890.00 | 60.4x | -168.2x | 6.9x |
| Mon, 13 Nov 2023 | SEK 160.8b | SEK 28.7b | -SEK 1,239,683,686.00 | 50.6x | -129.7x | 5.6x |
| Wed, 11 Oct 2023 | SEK 158.8b | SEK 27.4b | -SEK 2,015,877,318.00 | 49x | -78.8x | 5.8x |
| Fri, 08 Sep 2023 | SEK 151.3b | SEK 27.4b | -SEK 1,977,647,867.00 | 47.9x | -76.5x | 5.5x |
| Sun, 06 Aug 2023 | SEK 153.8b | SEK 27.5b | -SEK 1,574,427,530.00 | 54.3x | -97.7x | 5.6x |
| Tue, 04 Jul 2023 | SEK 160.1b | SEK 26.4b | -SEK 1,318,226,622.00 | 44.8x | -121.5x | 6.1x |
| Thu, 01 Jun 2023 | SEK 166.0b | SEK 26.3b | -SEK 1,209,449,751.00 | 44x | -137.2x | 6.3x |
| Sat, 29 Apr 2023 | SEK 175.8b | SEK 26.3b | -SEK 1,265,095,929.00 | 45.6x | -139x | 6.7x |
| Mon, 27 Mar 2023 | SEK 165.5b | SEK 25.4b | -SEK 2,031,671,425.00 | 39.2x | -81.5x | 6.5x |
| Wed, 22 Feb 2023 | SEK 171.3b | SEK 25.4b | -SEK 2,097,874,722.00 | 37.8x | -81.7x | 6.8x |
| Fri, 20 Jan 2023 | SEK 176.0b | SEK 23.8b | -SEK 1,843,117,918.00 | 32.1x | -95.5x | 7.4x |
| Sun, 18 Dec 2022 | SEK 158.6b | SEK 23.8b | -SEK 1,838,013,390.00 | 31.2x | -86.3x | 6.7x |
| Tue, 15 Nov 2022 | SEK 158.6b | SEK 23.9b | -SEK 1,905,469,956.00 | 32.2x | -83.2x | 6.6x |
| Thu, 13 Oct 2022 | SEK 151.2b | SEK 22.9b | -SEK 3,333,482,070.00 | 31x | -45.4x | 6.6x |
| Sat, 10 Sep 2022 | SEK 159.5b | SEK 22.9b | -SEK 3,243,830,491.00 | 34x | -49.2x | 7x |
| Mon, 08 Aug 2022 | SEK 169.8b | SEK 22.7b | -SEK 3,502,700,170.00 | 35.8x | -48.5x | 7.5x |
| Wed, 06 Jul 2022 | SEK 156.4b | SEK 21.4b | -SEK 3,521,696,527.00 | 36.7x | -44.4x | 7.3x |
| Fri, 03 Jun 2022 | SEK 156.0b | SEK 21.4b | -SEK 3,524,128,445.00 | 43.3x | -44.3x | 7.3x |
| Sun, 01 May 2022 | SEK 153.5b | SEK 20.0b | -SEK 3,342,880,997.00 | 46x | -45.9x | 7.7x |
| Tue, 29 Mar 2022 | SEK 166.0b | SEK 19.7b | -SEK 3,082,801,093.00 | 52.8x | -53.9x | 8.4x |
| Thu, 24 Feb 2022 | SEK 154.9b | SEK 19.7b | -SEK 2,536,169,254.00 | 50x | -61.1x | 7.9x |
| Sat, 22 Jan 2022 | SEK 168.7b | SEK 19.1b | -SEK 2,041,717,712.00 | 50.4x | -82.6x | 8.8x |
| Mon, 20 Dec 2021 | SEK 188.2b | SEK 19.0b | -SEK 1,992,145,647.00 | 52.7x | -94.5x | 9.9x |
| Wed, 17 Nov 2021 | SEK 202.0b | SEK 19.0b | -SEK 1,429,189,004.00 | 55.5x | -141.3x | 10.6x |
| Fri, 15 Oct 2021 | SEK 199.9b | SEK 18.1b | -SEK 1,345,834,061.00 | 42x | -148.5x | 11.1x |
| Sun, 12 Sep 2021 | SEK 219.2b | SEK 18.1b | -SEK 1,339,275,285.95 | 53.8x | -163.6x | 12.1x |
| Tue, 10 Aug 2021 | SEK 194.2b | SEK 18.1b | -SEK 1,175,418,285.95 | 55.6x | -165.3x | 10.7x |
Price to Earnings Ratio
-145.7x
Current Industry PE
- Investors are pessimistic on the Swedish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 7.4x is higher than the industry's current PS ratio of 6.4x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 19% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Swedish Healthcare industry?
| SE Market | -1.00% | |
| Healthcare | 0.28% | |
| Biotech | 1.47% | |
| Biotech | 1.47% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| SOBI Swedish Orphan Biovitrum | SEK 283.60 | 2.8% +SEK 2.6b | 36.2% | PE45x | |
| BONEX Bonesupport Holding | SEK 263.00 | 4.2% +SEK 696.6m | 106.6% | PE64.8x | |
| BIOA B BioArctic | SEK 228.80 | 1.3% +SEK 267.9m | -18.6% | PS80.1x | |
| DMYD B Diamyd Medical | SEK 14.84 | 10.3% +SEK 137.6m | 66.6% | PS7999.4x | |
| CRNO B Cereno Scientific | SEK 4.76 | 11.3% +SEK 135.4m | 615.2% | PS24.1x |